+13.1%
GSK vs AVAV
-68.0%
+81.2%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | AVAV | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | -8.3% | +13.4% | +5.1% |
| 7D | +4.9% | -10.1% | +15.0% | +5.0% |
| 30D | +9.9% | -18.7% | +28.6% | +10.1% |
| 3M | +0.2% | -33.0% | +33.2% | +0.5% |
| 6M | +2.3% | -37.2% | +39.5% | +2.8% |
| YTD | +7.1% | -53.2% | +60.3% | +7.5% |
| 1Y | +13.1% | -69.0% | +82.1% | +16.7% |
| All | +13.1% | -68.0% | +81.2% | +16.7% |
Cumulative growth
Daily Returns
Daily percentage return beside AVAV.
Daily Out/Under-Performance
Portfolio return minus AVAV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × AVAV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded AVAV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling